Press release
Uveal Neoplasms Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Target Population, Revenue, Statistics, MOA, ROA and Companies DelveInsight
Uveal Neoplasms Treatment Market
The Uveal Neoplasms market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Uveal Neoplasms market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Uveal Neoplasms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Uveal Neoplasms market.
Discover which therapies are expected to grab the Uveal Neoplasms Market Share @ Uveal Neoplasms Market Outlook- https://www.delveinsight.com/report-store/uveal-neoplasms-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Takeaways from the Uveal Neoplasms Market Report
• In March 2025, iOncture announced a phase II open-label, randomised, parallel-arm study, which will assess the clinical efficacy of oral roginolisib (IOA 244 [roginolisib hemi-fumarate]) as monotherapy against a control of Investigator ́s treatment choice in patients with advanced or metastatic uveal melanoma (UM). This study will enrol approximately 85 male and female patients aged over 18 years with advanced or metastatic UM, who have progressed following at least 1 prior immunotherapy treatment. The disease must be measurable (i.e., at least 1 measurable lesion) as per RECIST v1.1 by Computerised Tomography (CT) scan or Magnetic Resonance Imaging (MRI).
• In March 2025, IDEAYA Biosciences announced a study is designed as a multi-stage Phase 2 study within a Phase 3 study to evaluate the safety, tolerability, pharmacokinetics, dose-exposure relationship, and anti-tumor activity of IDE196 in combination with crizotinib compared to the comparator arm of investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).
• In March 2025, Replimune Inc. conducted a study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.
• The increase in Uveal Neoplasms Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Uveal Neoplasms Market is anticipated to witness growth at a considerable CAGR.
• The leading Uveal Neoplasms Companies such as Modulation Therapeutics Inc., NovoCure Ltd., Institut Curie, Iovance Biotherapeutics Inc., TriSalus Life Sciences Inc., Pfizer, Acrotech Biopharma Inc., Novartis Pharmaceuticals, Mirati Therapeutics Inc., BeiGene, Merck Sharp & Dohme LLC, Foghorn Therapeutics Inc., Bristol-Myers Squibb, and others.
• Promising Uveal Neoplasms Pipeline Therapies such as Tebentafusp, BVD-523, Tislelizumab, Sitravatinib Malate, Roginolisib, Pembrolizumab, Lenvatinib and others.
Stay ahead in the Uveal Neoplasms Therapeutics Market with DelveInsight's Strategic Report @ Uveal Neoplasms Market Outlook- https://www.delveinsight.com/sample-request/uveal-neoplasms-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Uveal Neoplasms Epidemiology Segmentation in the 7MM
The epidemiology section of Uveal Neoplasms offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.
Download the report to understand which factors are driving Uveal Neoplasms Epidemiology trends @ Uveal Neoplasms Prevalence- https://www.delveinsight.com/sample-request/uveal-neoplasms-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Uveal Neoplasms Drugs Market
The Uveal Neoplasms Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Uveal Neoplasms signaling in Uveal Neoplasms are likely to uncover new therapeutic targets and further expand treatment options for patients.
Uveal Neoplasms Treatment Market Landscape
The Uveal Neoplasms treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Uveal Neoplasms has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.
To learn more about Uveal Neoplasms treatment guidelines, visit @ Uveal Neoplasms Treatment Market Landscape- https://www.delveinsight.com/sample-request/uveal-neoplasms-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Uveal Neoplasms Market Outlook
The report's outlook on the Uveal Neoplasms market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Uveal Neoplasms therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Uveal Neoplasms drug and late-stage pipeline therapy.
Uveal Neoplasms Drugs Uptake
The drug chapter of the Uveal Neoplasms report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Uveal Neoplasms.
Major Uveal Neoplasms Companies
Modulation Therapeutics Inc., NovoCure Ltd., Institut Curie, Iovance Biotherapeutics Inc., TriSalus Life Sciences Inc., Pfizer, Acrotech Biopharma Inc., Novartis Pharmaceuticals, Mirati Therapeutics Inc., BeiGene, Merck Sharp & Dohme LLC, Foghorn Therapeutics Inc., Bristol-Myers Squibb, and others.
Learn more about the FDA-approved drugs for Uveal Neoplasms @ Drugs for Uveal Neoplasms Treatment- https://www.delveinsight.com/sample-request/uveal-neoplasms-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Uveal Neoplasms Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Uveal Neoplasms Companies- Modulation Therapeutics Inc., NovoCure Ltd., Institut Curie, Iovance Biotherapeutics Inc., TriSalus Life Sciences Inc., Pfizer, Acrotech Biopharma Inc., Novartis Pharmaceuticals, Mirati Therapeutics Inc., BeiGene, Merck Sharp & Dohme LLC, Foghorn Therapeutics Inc., Bristol-Myers Squibb, and others.
Uveal Neoplasms Pipeline Therapies- Tebentafusp, BVD-523, Tislelizumab, Sitravatinib Malate, Roginolisib, Pembrolizumab, Lenvatinib and others.
• Uveal Neoplasms Market Dynamics: Uveal Neoplasms Market Drivers and Barriers
• Uveal Neoplasms Market Access and Reimbursement, Unmet Needs and Future Perspectives
Discover more about Uveal Neoplasms Drugs in development @ Uveal Neoplasms Clinical Trials Assessment- https://www.delveinsight.com/sample-request/uveal-neoplasms-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Key Insights
2. Uveal Neoplasms Executive Summary
3. Competitive Intelligence Analysis for Uveal Neoplasms
4. Uveal Neoplasms: Market Overview at a Glance
5. Uveal Neoplasms: Disease Background and Overview
6. Patient Journey
7. Uveal Neoplasms Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Uveal Neoplasms Unmet Needs
10. Key Endpoints of Uveal Neoplasms Treatment
11. Uveal Neoplasms Marketed Products
12. Uveal Neoplasms Emerging Therapies
13. Uveal Neoplasms: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Uveal Neoplasms Market Outlook
16. Access and Reimbursement Overview of Uveal Neoplasms
17. KOL Views
18. Uveal Neoplasms Market Drivers
19. Uveal Neoplasms Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Trending Reports:
• Leptomeningeal Metastases Market: https://www.delveinsight.com/report-store/leptomeningeal-metastases-market
• Malt Lymphoma Market: https://www.delveinsight.com/report-store/malt-lymphoma-market
• Microsatellite Stable Colorectal Cancer Market: https://www.delveinsight.com/report-store/microsatellite-stable-colorectal-cancer-market
• Myelofibrosis Market: https://www.delveinsight.com/report-store/myelofibrosis-mf-market
• Necrotizing Enterocolitis Market: https://www.delveinsight.com/report-store/necrotizing-enterocolitis-market
• Neuroblastoma Market: https://www.delveinsight.com/report-store/neuroblastoma-market
• Neurofibromatosis 2 Market: https://www.delveinsight.com/report-store/neurofibromatosis-2-market
• Onycholysis Market: https://www.delveinsight.com/report-store/onycholysis-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/knee-osteoarthritis-market
• Palmar Hyperhidrosis Market Size: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Pcsk9 Inhibitor Market: https://www.delveinsight.com/report-store/pcsk9-inhibitors-psck9i-market
• Pd-1 & Pdl1 Market: https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape
• Pediatric Obesity Market: https://www.delveinsight.com/report-store/pediatric-obesity-market
• Penicillinbinding Proteins Market: https://www.delveinsight.com/report-store/penicillin-binding-proteins-market
• Polycythemia Vera Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Post-bariatric Hypoglycemia Market: https://www.delveinsight.com/report-store/post-bariatric-hypoglycemia-market
• Progressive Familial Intrahepatic Cholestasis Market: https://www.delveinsight.com/report-store/progressive-familial-intrahepatic-cholestasis-pfic-market
• Pulse Oximeter Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Radiation Toxicity Market: https://www.delveinsight.com/report-store/radiation-toxicity-market
• Rhino Conjunctivitis Market: https://www.delveinsight.com/report-store/allergic-rhino-conjunctivitis-market
• Sanfilippo Syndrome Market: https://www.delveinsight.com/report-store/sanfilippo-syndrome-market
• Severe Hypoglycemia Market: https://www.delveinsight.com/report-store/severe-hypoglycemia-market
• Small Fiber Neuropathy Market: https://www.delveinsight.com/report-store/small-fiber-neuropathy-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Uveal Neoplasms Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Target Population, Revenue, Statistics, MOA, ROA and Companies DelveInsight here
News-ID: 4114936 • Views: …
More Releases from DelveInsight Business Research
Global Occlusion Devices Market to grow at a CAGR of 6.31% by 2030, Evaluates De …
According to DelveInsight's analysis, The demand for occlusion devices is largely driven by the growing number of patients affected by various chronic conditions. Additionally, rapid technological advancements, rising preference for minimally invasive surgeries (MIS), favorable reimbursement policies for MIS, and an expanding geriatric population are key factors contributing to the overall growth of the occlusion devices market between 2024 and 2030.
DelveInsight's "Occlusion Devices Market Insights, Competitive Landscape and Market Forecast-2030"…
Hypoxia Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation b …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hypoxia pipeline constitutes key companies continuously working towards developing Hypoxia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Hypoxia Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hypoxia Market.
The Hypoxia Pipeline report embraces in-depth commercial and…
Hypoglycemia Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hypoglycemia pipeline constitutes 10+ key companies continuously working towards developing 12+ Hypoglycemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Hypoglycemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
Urinalysis Market to Reach USD 9.02 Billion by 2032, Growing at a 9.1% CAGR, Say …
According to DelveInsight's assessment, the rising prevalence of urinary disorders such as urinary tract infections (UTIs), chronic kidney disease, and hospital-acquired infections is driving strong demand for urinalysis testing, as early diagnosis is essential for timely and effective treatment.
Growing public awareness of health and wellness, along with government-led and private healthcare initiatives, is encouraging individuals to opt for routine diagnostic screenings. In parallel, educational efforts by healthcare providers continue…
More Releases for Uveal
Uveal Neoplasms Market Detailed Industry Report Analysis 2025-2034
Introduction
Uveal neoplasms, also referred to as uveal melanomas and related tumors, are rare malignancies that arise from the uveal tract of the eye, which includes the iris, ciliary body, and choroid. Among these, uveal melanoma is the most common primary intraocular malignancy in adults. Despite its rarity, it carries high morbidity and mortality risks, especially when it metastasizes to the liver.
Traditional management strategies - including surgery, radiotherapy, and enucleation -…
Metastatic Uveal Melanoma Therapeutics Market: An In-Depth Analysis
The Metastatic Uveal Melanoma Therapeutics market was valued at USD 1.23 billion in 2023 and is projected to reach approximately USD 3.00 billion by 2033, growing at an estimated CAGR of around 8.9% from 2024 to 2033.
Metastatic Uveal Melanoma Therapeutics Market Overview
The Metastatic Uveal Melanoma Therapeutics market is evolving rapidly with the emergence of novel targeted and immunotherapeutic treatments addressing this rare and aggressive cancer. Increasing research into tumor-specific pathways…
Global Uveal Melanoma Treatment Market Will Generate Record Revenue by 2028
This Uveal Melanoma Treatment market report is the product of thorough market study and comments on important factors that influence financial decision. Here, helpful insights on customer demands are provided in order to launch the best product or service on the market. COVID-19's detrimental effects on the world economy system are also captured in this way. As a result of the pandemic, some businesses experienced considerable financial losses. Several businesses…
Uveal Melanoma Therapeutics- Clinical Trials & Results | HARMONIC PHARMA, Immuno …
Uveal melanoma is the most common primary malignant tumour of intraocular malignancy, arises from melanocytes in the iris, and ciliary body.
Download the sample report @ https://www.pharmaproff.com/request-sample/1121
The most common symptoms of uveal carcinoma include blurred vision, photopsia, visual field loss, visible tumour, pain, and metamorphopsia. The management of uveal melanoma can be divided into globe-preserving therapy or enucleation. Globe-preserving therapies can broadly classified into radiation, surgical, and laser therapy.
Get…
Uveal Melanoma Global Market Research Report 2025
Uveal Melanoma Report by Material, Application, and Geography � Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China).
Access more details about this report at: https://www.research2reports.com/report-medical-devices/uveal-melanoma-market/80986
The report firstly introduced the Uveal Melanoma basics: definitions, classifications, applications and…
Uveal Melanoma Market By Analysis of Major Industry Segments 2024
Global Uveal Melanom Market: Overview
Uvea is present posterior to sclera and the cornea and has three parts namely, iris, ciliary body and choroid. Uveal melanoma is referred as the cancer of the parts of eye including the iris choroid and ciliray body. It is the condition in which the tumors arise from the melanocytes residing within the uva responsible for the color of the eye. Though is a rare…
